Effects of the hinge region of cecropin A(1–8)–magainin 2(1–12), a synthetic antimicrobial peptide, on liposomes, bacterial and tumor cells  by Shin, Song Yub et al.
E¡ects of the hinge region of cecropin A(1^8)^magainin 2(1^12), a
synthetic antimicrobial peptide, on liposomes, bacterial and tumor cells
Song Yub Shin a, Joo Hyun Kang a, So Yun Jang a, Yangmee Kim b,
Kil Lyong Kim a, Kyung-Soo Hahm a;*
a Peptide Engineering Research Unit, Korea Research Institute of Bioscience and Biotechnology, P.O. Box 115, Yusong,
Taejon 305-600, South Korea
b Department of Chemistry, Konkuk University, Seoul 143-701, South Korea
Received 28 June 1999; received in revised form 5 October 1999; accepted 5 October 1999
Abstract
A 20-residue hybrid peptide (CA(1^8)^MA(1^12): KWKLFKKIGIGKFLHSAKKF^NH2) incorporating 1^8 residues of
cecropin A (CA) and 1^12 residues of magainin 2 (MA) has potent antibiotic activity without hemolytic activity. In order to
investigate the effects of the flexible hinge sequence, Gly^Ile^Gly of CA(1^8)^MA(1^12) (CA^MA) on antibiotic activity,
CA^MA and its three analogues, CA^MA1, CA^MA2 and CA^MA3 were synthesized. The Gly^Ile^Gly sequence of CA^
MA was deleted in CA^MA1 and replaced with Pro and Gly^Pro^Gly in CA^MA2 and CA^MA3, respectively. CA^MA1
and CA^MA3 caused a significant decrease in the bactericidal rate against Escherichia coli and Bacillus subtilis and the
tumoricidal activity against four different tumor cells, and the PC/PS (4:1, w/w) vesicle-aggregating and disrupting activities.
However, CA^MA2 showed a similar bactericidal rate and antitumor, vesicle-aggregating and disrupting activities, as
compared with CA^MA. These results suggested that the flexibility or L-turn induced by Gly^Ile^Gly or Pro in the central
part of CA^MA may be important in the electrostatic interaction of the cationic short K-helical region in the N-terminus with
the cell membrane surface and the hydrophobic interaction of amphipathic K-helical region in the C-terminus with the
hydrophobic acyl chains in the cell membrane. CA^MA3 exhibited lower activity in antibacterial, antitumor, and vesicle-
aggregating and disrupting activities than CA^MA and CA^MA2. This result suggested that the excessive L-turn structure by
Gly^Pro^Gly in CA^MA3 seems to interrupt the ion channel/pore formation on the lipid bilayer. It was concluded that the
appropriate flexibility or L-turn structure provided by the central hinge is responsible for the effective antibiotic activity of
the antimicrobial peptides with the helix^hinge^helix structure. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
In recent years, the antimicrobial peptides have
become recognized as an important component of
the non-speci¢c host defense system and innate im-
munity of insects, amphibians, and mammals. Cecro-
pin A (CA), one of the ¢rst reported peptides of
these antimicrobial peptides, is found in the hemo-
lymph of Hyalophora cecropia pupae and consists of
37 amino acid residues [1^5]. Magainin 2 (MA), a
23-amino acid antimicrobial peptide, is identi¢ed
from the skin of the African clawed frog Xenopus
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laevis [6^9]. CA and MA display strong bacteriolytic
activity against Gram-positive and Gram-negative
bacteria, but have no toxicity against normal eukary-
otic cells such as erythrocytes [4,7^9]. The antibacte-
rial activity of these two peptides has been related to
their ability to adopt an amphipathic K-helical con-
formation. Melittin (ME), a 26-residue peptide de-
rived from honey bee venom, shows powerful anti-
bacterial properties, but is very cytotoxic (e.g.,
hemolytic) for normal eukaryotic cells [10,11]. The
recent emergence of drug resistant bacteria, fungi,
and parasites has resulted in a considerable interest
in using endogenous antimicrobial peptides as ther-
apeutic agents.
Peptide antibiotics as therapeutic agents should act
against a very wide range of bacterial cells but have
no cytotoxicity on normal eukaryotic cells. In the
course of systematic studies aimed at ¢nding antibi-
otic peptides having improved antibacterial activity
without toxic e¡ect on normal eukaryotic cells such
as erythrocytes, a series of CA^ME hybrid peptides
composed from the N-terminal cationic amphipathic
region of CA and the N-terminal hydrophobic region
of ME were synthesized [11^13]. These CA^ME hy-
brid peptides displayed more e¡ective antibacterial
activity than parental CA and less toxicity against
erythrocytes than ME [11^13]. In our previous study,
CA(1^8)^ME(1^12), one of these hybrid peptides,
was found to have e¡ective antibacterial activity,
but is very hemolytic at high peptide concentration
(e.g., 100 WM).
Also in our previous study, CA(1^8)^MA(1^12)
(CA^MA), composed of the amino terminal se-
quence of CA and MA, was found to display similar
antibacterial and antitumor activities, as compared
with CA(1^8)^ME(1^12), but it showed no hemolytic
activity until 100 WM [14^17]. CA(1^8)^MA(1^12)
(CA^MA) and CA(1^8)^ME(1^12) (CA^ME) are
composed of an N-terminal cationic, a short K-helix
and a C-terminal amphipathic K-helix joined by a
£exible hinge sequence of Gly9^Ile10^Gly11. The cat-
ionic amphipathic helix^hinge^hydrophobic helix ar-
rangement is a common structural motif found in the
antimicrobial peptides such as CA, cecropin B(CB),
and pardaxin [17^23]. Cationicity and amphipathic-
ity of these peptides are believed to facilitate initial
electrostatic contact with polyanionic sites in the wall
or membrane of the target microorganism and are
essential for the membrane-disruptive ability [24^
34]. However, the e¡ects of the hinge region of these
peptides on antibiotic activity against bacterial and
tumor cells have not yet been investigated.
Therefore, in the present study, the e¡ects of the
deletion (CA^MA1) and substitution with Pro (CA^
MA2), a helix breaker or Gly^Pro^Gly (CA^MA3),
a L-turn inducer at the £exible hinge sequence (Gly9^
Ile10^Gly11) in CA^MA on the antibacterial, antitu-
mor, and vesicle-aggregating and disrupting activities
were investigated (Table 1). The vesicle-disrupting
activities of the peptides were investigated by the
measurement of released dye from dye-encapsulating
vesicles. Human erythrocyte and a mouse ¢broblast
cell line were used to measure the cytotoxicity of the
peptides against normal eukaryotic cells. The second-
ary structures of the peptides were investigated by
circular dichroism (CD) in the membrane-mimicking
environment, such as tri£uoroethanol (TFE), sodium
dodecyl sulfate (SDS).
2. Materials and methods
2.1. Peptide synthesis and puri¢cation
The peptides were synthesized by the solid phase
method [35] using Fmoc(9-£uorenylmethoxycarbon-
yl)-chemistry (Table 1). Rink Amide 4-methylbenz-
hydryl-amine (MBHA) resin (0.55 mmol/g) was
Table 1
Amino acid sequences of CA^MA and its analogues
Peptide Amino acid sequence Remarks
CA^MA KWKLFKKIGIGKFLHSAKKF^NH2 CA(1^8)^MA(1^12)
CA^MA1 KWKLFKKI99KFLHSAKKF^NH2 CA(1^8)^MA(1^12):G9I10G11 deletion
CA^MA2 KWKLFKKIÿPÿKFLHSAKKF^NH2 CA(1^8)^MA(1^12):G9I10G11CP
CA^MA3 KWKLFKKIGPGKFLHSAKKF^NH2 CA(1^8)^MA(1^12): I10CP
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used as the support to obtain a C-terminal amidate
peptide. The coupling of Fmoc-amino acids was per-
formed with N-hydroxybenzotriazole (HOBt) and di-
cyclohexylcarbodiimide (DCC). Amino acid side
chains were protected as follows: t-butyl (Ser and
Thr), trityl (His), t-butyloxycarbonyl (Lys). Depro-
tection and cleavage from the resin were carried
out using a mixture of tri£uoroacetic acid, phenol,
water, thioanisole, 1,2-ethanedithiol and triisopropyl-
silane (82.5:5:5:5:2.5:2, v/v) for 2 h at room temper-
ature. The crude peptide was then repeatedly washed
with diethylether, and dried in a vacuum. The crude
peptides were puri¢ed by a reversed-phase prepara-
tive HPLC on a Waters 15-Wm Deltapak C18 column
(19U30 cm). Purity of the puri¢ed peptides was con-
¢rmed by analytical reversed-phase HPLC on an Ul-
trasphere C18 column (Beckman, USA), 4.6U25 cm.
The puri¢ed peptides were hydrolyzed with 6 N HCl
at 110‡C for 22 h, and then dried in a vacuum. The
residues were dissolved in 0.02 N HCl and subjected
to an amino acid analyzer (Hitachi Model 8500 A,
Japan). The amino acid composition of the synthetic
peptides was con¢rmed by amino acid analysis. The
molecular masses of the synthetic peptides were de-
termined with MALDI (matrix-assisted laser desorp-
tion/ionization) mass spectra.
2.2. Hemolytic activity
The hemolytic activity of the peptides was eval-
uated by determining hemoglobin release of 4% sus-
pensions of fresh human erythrocytes at 414 nm.
Human red blood cells were centrifuged and washed
three times with phosphate-bu¡ered saline (PBS: 35
mM phosphate bu¡er/0.15 M NaCl, pH 7.0). One
hundred Wl of human red blood cells suspended 8%
(v/v) in PBS were plated into 96-well plates, and then
100 Wl of the peptide solution was added to each
well. The plates were incubated for 1 h at 37‡C,
and centrifuged at 150Ug for 5 min. One-hundred-
Wl aliquots of the supernatant were transferred to 96-
well plates. Hemolysis was measured by absorbance
at 414 nm with an ELISA plate reader (Molecular
Devices Emax, Sunnyvale, CA, USA). Zero percent
hemolysis and 100% hemolysis were determined in
PBS and 0.1% Triton-X 100, respectively. The he-
molysis percentage was calculated using the follow-
ing equation: % hemolysis = [(Abs414 nm in the pep-
tide solution3Abs414 nm in PBS)/(Abs414 nm in 0.1%
Triton X-1003Abs414 nm in PBS)]U100.
2.3. Antibacterial activity
Escherichia coli (KCTC cat. no. 1682), Salmonella
typhimurium (KCTC cat. no. 1926), Pseudomonas
aeruginosa (KCTC cat. no. 1637), Bacillus subtilis
(KCTC cat. no. 1918), Streptococcus pyogenes
(KCTC cat. no. 3096), and Staphylococcus aureus
(KCTC cat. no. 1621) were supplied by the Korean
Collection for Type Cultures (KCTC), Korea Re-
search Institute of Bioscience and Biotechnology
(Taejon, Korea). The bacteria were grown to the
mid-logarithmic phase in a medium (g/l) (10 bacto-
tryptone/5 yeast extract/10 NaCl (pH 7.0)). The pep-
tides were stepwise-diluted in a medium of 1% bac-
topeptone. The tested organism (¢nal bacterial
suspension: 2U106 colony formation units (CFU)/
ml) suspended in growth medium (100 Wl) was mixed
with 100 Wl of the test peptide solution in a microtiter
plate well with three replicates for each test solution.
Microbial growth was determined by the increase in
optical density at 620 nm after 10 h incubation at
37‡C. The minimal inhibitory concentration (MIC)
was de¢ned as the lowest concentration of peptide
at which there was no change in optical density.
2.4. Growth inhibitory activity on tumor cells and
normal cell
Growth inhibitory activity of the peptides against
cancer and normal ¢broblast cells was determined as
50% inhibition concentration (IC50) using a tetrazo-
lium (MTT) colorimetric assay. Human chronic mye-
logenous leukemia (K-562: ATCC cat. no. CCL-
243), human acute T-cell leukemia (Jurkat: ATCC
cat. no. TIB-152), human lung carcinoma cancer cells
(K-549: ATCC cat. no. CCL-185) and human breast
adenocarcinoma cell (MDA-MB-361: ATCC cat. no.
HTB-27) were used for the growth inhibitory activity
assay of the peptides against cancer cells. Mouse
NIH-3T3 ¢broblast cell (ATCC cat. no. CRL-1658)
were used for growth inhibitory activity assay of the
peptides against normal cells. These cells were ob-
tained from the Genetic Resources Center of Korea
Research Institute of Bioscience and Biotechnology
(Taejon, Korea). The cells were grown in a RPMI-
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1640 medium supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS), 100 units/ml penicil-
lin G sodium, and 100 Wg/ml streptomycin sulfate.
The cells were plated on 96 well plates at a density
of 2.0U104 cells/well in 150 Wl of the same medium.
After incubating the plates overnight at 37‡C in 5%
CO2 atmosphere, 20 Wl of serially diluted peptides
were added and then incubated for 3 days. Twenty
Wl of MTT solution (5 mg/ml MTT in phosphate-
bu¡ered saline) was added to each well and the
plates were incubated at 37‡C for 4 h. Forty Wl of
20% SDS solution containing 0.02 M HCl was added
to dissolve the dark-blue crystals which formed
(MTT-formazan product) in each well, and then in-
cubated overnight. Absorbance was measured at
570 nm on an ELISA plate reader (Molecular Devi-
ces Emax).
2.5. Kinetics of bacterial killing
The kinetics of bacterial killing of the peptides
were evaluated using E. coli and B. subtilis. Log-
phase bacteria (6U105 CFU/ml) were incubated
with 2.5 WM peptide in LB broth. Aliquots were
removed at ¢xed time intervals, appropriately di-
luted, plated on LB broth agar plate, and then the
colony-forming units were counted after 16^18 h in-
cubation at 37‡C.
2.6. Determination of vesicle aggregation
Phospholipid vesicle aggregating activity of the
peptides was measured by the changes in turbidity
at 400 nm using a Beckman DU-8 spectrophotome-
ter (Palo Alto, CA, USA). Phospholipid vesicle sus-
pension composed of phosphatidylcholine (PC)/phos-
phatidylserine (PS) (4:1, w/w) was prepared in Hepes
bu¡er (10 mM Hepes, 150 mM NaCl, pH 7.4) to give
a ¢nal concentration of 35 WM by the sonication
process [36]. Various amounts of the peptides were
added to the vesicle suspension to obtain various
ratios of peptide to phospholipid.
2.7. Carboxy£uorescein leakage measurements
Carboxy£uorescein (CF)-encapsulated large unila-
mellar vesicles (LUV) composed of PC/PS (4:1, w/w)
were prepared by the reversed-phase ether evapora-
tion method [37] using 100 mM CF. The initially
formed vesicles were extruded through Nucleopore
¢lter of 0.1 Wm. To remove free CF dye, the vesicles
were passed through a Bio-Gel A 0.5m (Bio-Rad,
Richmond, USA) column (1.5U30 cm) using phos-
phate-bu¡ered saline (pH 7.4) as the eluting bu¡er.
The separated LUV fraction, after appropriate dilu-
tion to a ¢nal concentration of 6.36 WM, was mixed
with the peptide solution in a 2 ml cuvette at 25‡C.
The leakage of CF from the LUV was monitored by
measuring £uorescence intensity at 520 nm excited at
490 nm on a Shimadzu RF-5000 spectro£uorometer
(Tokyo, Japan). The apparent percent leakage value
at a £uorescence intensity, F, was calculated by the
following equation:
% leakage apparent  100UF3F0=F t3F0
Ft denotes the £uorescence intensity corresponding
to 100% leakage after the addition of 20 Wl of 10%
Triton X-100. F0 represents the £uorescence of the
intact vesicle.
2.8. Circular dichroism (CD) spectroscopy
CD spectra of peptides were recorded using a Jas-
co J720 spectropolarimeter using a 1 mm pathlength
cell (Japan). The CD spectra of the peptides in
10 mM sodium phosphate bu¡er (pH 7.2), 50%
(v/v) TFE, or 30 mM SDS were recorded at 25‡C
in the 190^240 nm wavelength range at 0.1-nm inter-
vals. The peptide concentrations were 100 Wg/ml. The
mean residue ellipticity [a] was calculated using the
molecular mass of each peptide as determined from
the amino acid composition. The percentage helicity
of the peptides were calculated with the equation
[38]: % helix = 100a 2223a 0222=a 100222, where [a]222
is the observed mean residue ellipticity per residue at
222 nm in degccm2 dmol31. a 0222 and a 100222 are the
estimated ellipticities corresponding to a random coil
(31000 degccm2 dmol31) and 100% helical peptides
(336 500 degccm2 dmol31), respectively.
3. Results
3.1. Antibacterial, antitumor and hemolytic activity
Antibacterial activity of the peptides was deter-
BBAMEM 77754 26-1-00
S.Y. Shin et al. / Biochimica et Biophysica Acta 1463 (2000) 209^218212
mined as minimal inhibitory concentration (MIC)
value against Gram-positive and Gram-negative bac-
terial strains (Table 2). All peptides completely in-
hibited the growth of all bacteria strains tested with
MIC values from 0.78 to 6.25 WM. As shown in
Table 2, the deletion (CA^MA1) and Pro (CA^
MA2) or Gly^Pro^Gly substitution (CA^MA3) of
Gly^Ile^Gly sequence in CA^MA had no signi¢cant
e¡ect on bactericidal activity after long-time incuba-
tion. Since CA^MA and its analogues show similar
MIC values on bacterial strains tested, the time
course of the peptides to kill mid-logarithmic phase
of E. coli and B. subtilis were compared. As shown in
Fig. 1, CA^MA and CA^MA2 displayed faster bac-
tericidal rate against both E. coli and B. subtilis than
CA^MA1 and CA^MA3. These results indicate that
the Gly^Ile^Gly hinge sequence or L-turn inducing
Pro residue in the central region of CA^MA have an
important role in the bactericidal rate against both
E. coli and B. subtilis. The excessive £exible L-turn
structure induced by Gly^Pro^Gly substitution in the
central hinge region of CA^MA brought about a
drastic reduction in the bactericidal rate for E. coli
and B. subtilis. This fact suggests that the appropri-
ate £exibility in the central hinge region of CA^MA
is more responsible for the bactericidal rate against
E. coli and B. subtilis than bactericidal activity.
The cytotoxicity against normal eukaryotic cells of
the peptides was measured by monitoring the hemo-
globin released from incubating 4% human red blood
cell suspension with 100 WM peptide. None of the
peptides exhibited any hemolytic activity below 100
WM. The IC50 of the peptides on the four di¡erent
tumor cells were obtained from the plots of cell sur-
vival (%) versus the concentration of the peptides
(Fig. 2). The IC50 values of the peptides against the
four di¡erent tumor cells are summarized in Table 2.
The deletion and Gly^Pro^Gly substitution of Gly^
Ile^Gly in CA^MA caused a signi¢cant reduction in
the tumoricidal activity against tumor cells. In addi-
tion, CA^MA2 with Pro substitution in the hinge
region of CA^MA showed a 1.5^2.0 times greater
tumoricidal activity than CA^MA.
All the peptides displayed higher IC50 values
(s 100 WM) in growth inhibition against normal
NIH-3T3 ¢broblast cells (Table 2). The signi¢cant
di¡erence in growth inhibitory activity of all the pep-
tides between normal and transformed eukaryotic
cells may be due to the outer membrane surface of
transformed tumor cells having more exposed
anionic lipids than that of normal cells.
3.2. Peptide-induced vesicle aggregation and
disruption
To elucidate the peptide-induced dye leakage out
Table 2
Antibacterial, antitumor and hemolytic activities of CA^MA and its analogues
Cell types CA^MA CA^MA1 CA^MA2 CA^MA3
Gram-negative bacteria (MIC: WM) E. coli 3.125 6.25 6.25 3.125
S. typhimurium 0.78 0.78 0.78 0.78
P. aeruginosa 1.56 1.56 3.125 0.78
Gram-positive bacteria (MIC: WM) B. subtilis 0.78 1.56 1.56 0.78
S. pyogenes 0.78 0.78 0.78 0.78
S. aureus 3.125 3.125 3.125 3.125
Tumor cells (IC50 : WM) K-562 65.0 85.3 35.1 s 100
A-549 60.0 100 25.0 s 100
Jurkat 30.0 65.0 20.0 75.0
MDA-MB-361 44.0 100 28.0 s 100
Normal cell (IC50 : WM) NIH-3T3 ¢broblast s 100 s 100 s 100 s 100
% Hemolysis (100 WM) Human erythrocytes 0 0 0 0
Minimal inhibitory concentrations were determined by incubating approximately 2U106 CFU/ml of cells with serial dilutions of a 96-
well microtiter plate. Bacterial growth was assessed optical density measurement at 620 nm. The lowest concentration of the peptides
that any suppression of bacterial growth was de¢ned MIC. The 50% inhibition concentration (IC50) of the peptides against NIH-3T3
¢broblast cell and four tumor cells was determined using the MTT assay. Hemolytic activity of each peptide was determined using hu-
man erythrocytes. The release of hemoglobin was monitored by measuring the optical density at 414 nm, as compared with that of
the cell suspension treated with 0.1% Triton X-100, was de¢ned % hemolysis.
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of phospholipid vesicles, the vesicle aggregation
event was examined as the initial step in the pep-
tide^vesicle interaction process. The changes in
vesicle size due to aggregation could be monitored
by the absorbance of vesicle suspension at 400 nm.
The light scattering intensity is known to be quite
sensitive to particle size. Fig. 3 showed the changes
in absorbance at 400 nm as a function of concentra-
tion of the added peptide to the PC/PS (4:1, w/w)
vesicle. When CA^MA2 was added to the PC/PS
vesicle solution, a sharper increase and a higher ab-
sorbance intensity due to e¡ective aggregation was
observed. These aggregation events induced by pep-
tides might result from the interaction of negatively-
charged PS and these cationic peptides. This sugges-
tion was supported by the results that these peptides
did not induce the aggregation of PC vesicle, zwit-
terionic phospholipid, and the aggregation e⁄cien-
cies were dependent on the PS content of the used
vesicle (Fig. 3, inset).
The interaction of the peptides with phospholipid
vesicles was further investigated by measuring the
ability of the peptides to perturb the PC/PS (4:1)
LUV (Fig. 4). CA^MA2, the most e¡ective peptide
in inducing vesicle aggregation, exhibited the highest
activity in the vesicle disruption (Fig. 4). This result
suggested that the relative e⁄ciencies of these pep-
tides to perturb the lipid membranes were correlated
with their vesicle aggregation activities. The release
of CF from the vesicle was dependent on the concen-
tration of peptides in the vesicle suspension. The ex-
Fig. 1. Kinetics of killing E. coli and B. subtilis by CA^MA and its analogues. Bacteria, either untreated (F) or treated with 2.5 WM
CA^MA (b), 2.5 WM CA^MA1 (a), 2.5 WM CA^MA2 (S), or 2.5 WM CA^MA3 (P), were diluted at the indicated time intervals,
and then plated on LB broth agar. The colony-forming units were calculated by counting the plates after 16^18 h incubation at 37‡C.
Fig. 2. Concentration^response curves of CA^MA (b), CA^
MA1 (a), CA^MA2 (S) and CA^MA3 (P) in growth inhibi-
tion against three di¡erent transformed tumor cells.
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tent of CF release induced by CA^MA as a function
of peptide to lipid molar ratio (P/L) was found to be
a sigmoidal pattern (Fig. 4, inset), but those of other
peptides were hyperbolic curves. This might indicate
that an accumulation of CA^MA is involved in the
CA^MA-induced vesicle leakage process.
In order to investigate the membrane-interacting
mechanisms of CA^MA and its analogues, the
vesicle aggregation and perturbation activities by
peptides were observed with the PC/PS (4:1) vesicle
as the arti¢cial model membrane. These peptides in-
duced not only the aggregation but also the pertur-
bation of vesicles in a dose-dependent manner. The
importance of electrostatic interactions in the pep-
tide^lipid vesicle was suggested by the results that
CA^MA and its analogues speci¢cally induced the
aggregation of the vesicle containing negatively-
charged phospholipid and the reduced aggregation
e⁄ciency by the addition of zwitterionic PC to PS
membrane. The aggregation e⁄ciency of phospholip-
id vesicle by CA^MA increased in the order to PS
vesiclesPC/PS (1:1, w/w) vesiclesPC/PS (4:1,
w/w)EPC vesicle (Fig. 3, inset). When the peptide
was added to phospholipid vesicle solution, the pos-
itively charged region of the peptide was electrostati-
cally attracted to the negatively charged head group
of acidic phospholipid, PS and then the membrane-
induced K-helical region might penetrate the lipid
bilayer.
3.3. Peptide structural analysis
Many antimicrobial peptides including cecropins
and magainins adapt the K-helical structure in mem-
brane-mimetic environments such as TFE, SDS mi-
celles or liposome [27^31]. The CD spectra of the
peptides were measured in phosphate bu¡er with or
without the K-helix inducing solvent TFE or SDS
composed of an aliphatic tail and a negatively
charged head group mimicked the lipid membrane.
As shown in Fig. 5, the CD spectrum indicated that
CA^MA and its analogues have random coil confor-
mations in phosphate bu¡er, while form a well-de-
¢ned K-helical structure in the presence of 50% TFE
and 30 mM SDS. All the peptides showed higher K-
helical content in 50% TFE than 30 mM SDS (Fig. 5,
Table 3).
In 50% TFE solution, the deletion of Gly^Ile^Gly
(CA^MA1) in CA^MA did not a¡ect the K-helical
content. In contrast, it resulted in about a twofold
Fig. 4. Release of CF from LUVs composed of PC/PS (4:1,
w/w). The extents of vesicle disruption induced by peptide were
indicated as a function of peptide to lipid ratio (P/L). The re-
leased CF £uorescence was measured at Vex = 490 nm and
Vem = 520 nm. Inset: the %CF release at low P/L ratio. (b)
CA^MA; (a) CA^MA1; (S) CA^MA2; (P) CA^MA3.
Fig. 3. Monitoring the phospholipid vesicle (PC/PS = 4:1, w/w)
aggregation induced by peptides. The vesicle aggregation was
determined by measuring the absorbance at 400 nm in 10 mM
Hepes bu¡er containing 150 mM NaCl (pH 7.4). (b) CA^MA;
(a) CA^MA1; (S) CA^MA2; (P) CA^MA3. Inset: the aggre-
gation e⁄ciency of phospholipid vesicle depending on the PS
content induced by CA^MA. (b) PS vesicle ; (a) PC/PS (1:1,
w/w) vesicle ; (P) PC/PS (4:1, w/w) vesicle; (S) PC vesicle.
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increase of K-helical content in 30 mM SDS micelle.
Substitution of Pro (CA^MA2) for Gly^Ile^Gly in
CA^MA caused about a twofold decrease in K-heli-
cal content in both 50% TFE and 30 mM SDS solu-
tion. Substitution of Gly^Pro^Gly (CA^MA3) for
Gly^Ile^Gly in CA^MA resulted in a slight increase
of K-helical content in SDS micelle. Nevertheless,
none of all the peptides showed a signi¢cant di¡er-
ence in K-helical content in cell membrane mimicking
environment such as TFE solution and SDS micelles,
Fig. 5. CD spectra of CA^MA and its analogues in the solutions of 30 mM SDS (dashed line), 0 (solid line), and 50% (v/v) TFE
(dotted line), respectively, containing 10 mM sodium phosphate bu¡er, pH 7.2.
Table 3
Percent K-helicity of CA^MA and its analogues in various solution
Peptide Bu¡er 50% TFE 30 mM SDS
[a]222 K-helix (%) [a]222 K-helix (%) [a]222 K-helix (%)
CA^MA 1170 5.9 320 860 54.4 36140 14.1
CA^MA1 1930 8.0 321 450 56.0 311 080 27.6
CA^MA2 1800 7.7 310 450 28.9 35 810 13.2
CA^MA3 420 3.9 315 040 38.5 37 470 17.7
The percent K-helicity of the peptides were calculated with the equation: % helix = 100a 2223a 0222=a 100222.
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they had di¡erent lytic abilities against bacterial and
tumor cells. This indicates that the K-helical structur-
al characteristic of the peptide may play an impor-
tant role in killing bacterial and tumor cells, but its
K-helical content may not be correlated to their anti-
bacterial and antitumor activities.
4. Discussion
The hybrid peptide, CA^MA, was found to have
e¡ective antibacterial activity against Gram-positive
and Gram-negative bacterial strains and even potent
antitumor activity against some transformed tumor
cells, but it had no hemolytic e¡ect for human eryth-
rocytes [14^17]. Unlike CA and CB with amphi-
pathic helix^£exible^hydrophobic helix motif, CA^
MA has the structural motif of the cationic short
helix^£exible^amphipathic helix. In our previous
study, the Gly^Ile^Gly sequence in the tertiary struc-
ture of CA^MA in an aqueous 50% TFE solution
determined by two-dimensional NMR study was ob-
served to be rather £exible [39]. This £exible se-
quence in the central region of CA^MA is thought
to play an important role in antibiotic activity
against bacterial and tumor cells and disrupting abil-
ity for arti¢cial lipid bilayers. Therefore, in this
study, the e¡ect of the £exible Gly^Ile^Gly sequence
of CA^MA on its antibiotic activity against bacterial
and tumor cells and the vesicle-aggregating and dis-
rupting abilities was investigated.
Deletion of Gly^Ile^Gly (CA^MA1) and substitu-
tion of Gly^Pro^Gly (CA^MA3) in CA^MA did not
a¡ect antibacterial activity (MIC value) against
Gram-positive and Gram-negative bacterial strains
induced by long-term peptide incubation. In con-
trast, CA^MA1 and CA^MA3 resulted in a signi¢-
cant decrease in the bactericidal rate against E. coli
and B. subtilis and the tumoricidal activity against
the four di¡erent transformed cancer cells, and the
PC/PS vesicle-aggregating and disrupting activities.
However, CA^MA2 with Pro residue instead of
Gly^Ile^Gly sequence of CA^MA showed similar
antitumor activity, and bactericidal rate against E.
coli and B. subtilis and PC/PS vesicle-aggregating
and disrupting activities when compared with CA^
MA.
The Gly^Ile^Gly and Pro in the tertiary structure
of CA^MA and CA^MA2 in dodecylphosphocholine
(DPC) micelles determined by two-dimensional
NMR analysis was found to have almost similar
£exibility (unpublished data). Accordingly, these re-
sults suggested that the £exibility or bent potential
induced by Gly^Ile^Gly sequence or Pro residue in
the central part of CA^MA may be important in the
electrostatic interaction of the cationic short K-helical
region in the N-terminus with the cell membrane sur-
face and the hydrophobic interaction of amphipathic
K-helical region in the C-terminus with the hydro-
phobic acyl chains in the cell membrane. CA^MA3
exhibited lower activity in antibacterial, antitumor,
and vesicle-aggregating and disrupting activities
than CA^MA and CA^MA2. This result suggests
that the extended turn structure provided by Gly^
Pro^Gly in CA^MA3 seems to interrupt the ion
channel/pore formation on the cell membrane.
Also, in our previous study, the substitution of
Gly^Pro^Gly for Gly^Ile^Gly in CA(1^13)^MA(1^
13) and CA(1^13)^ME(1^13) hybrid peptides re-
sulted in a drastic reduction in both antibacterial
and antitumor activity [17]. In contrast, the substitu-
tions of Gly^Pro, Pro, or Gly^Ile for Gly^Ile^Gly of
CA^MA analogue (L^CA^MA: KWKLFKKI-
GIGFLHLAKKF^NH2) retained good antibacterial
and antitumor activity [17].
Therefore, our results indicated that appropriate
£exibility or bend potential provided by Gly^Pro,
Pro, or Gly^Ile for Gly^Ile^Gly in the central hinge
region which connects the cationic K-helical N-termi-
nus and the amphipathic K-helical C-terminus of the
antimicrobial peptides is responsible for their e¡ec-
tive antibacterial and antitumor activity with no or
less cytotoxicity against normal eukaryotic cells. The
lytic activity induced by CA^MA and its analogues
was less e¡ective for the normal cells than for tumor
cells. It was reported that the anionic phospholipids
such as phospatidylserine (PS) in the outer mem-
brane lea£et of human tumor cells is highly exposed
[40].
Also, as shown in Fig. 4, the vesicle-aggregation
activity of CA^MA increased with increasing of PS
content of the phospholipid vesicle. Therefore, the
di¡erence in cytotoxic e¡ect of CA^MA and its ana-
logues between tumor and normal cells is due to the
peptides interacting strongly with the anionic phos-
pholipids on the cell surface of the tumor cells. This
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interpretation may be supported by Chen et al.’s
study [41]: CB-1 having more positive charged resi-
dues was more e¡ective for HL-60, K-562, Jurkat
and CCRF-CEB leukemia cancer cells than CB. Ac-
cordingly, these results suggest that the electrostatic
attraction of the peptides to the anionic phospholip-
ids on the cell surface may be one of the main driv-
ing forces before lysis in membrane bilayers can be
e⁄ciently initiated.
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